Showing results (171-180 of 222) with videos related to
Sort By:
Pageof 23
Prostate Cancer and Prostatic Diseases|January 21, 2015
Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxelH H Cheng, R Gulati, A Azad, et al.JCO Precision Oncology|September 16, 2025
Multicenter Phase II Study of Olaparib and the ATR Inhibitor Ceralasertib in Metastatic Castration-Resistant Prostate Cancer (TRAP)Irene Tsung, David C Smith, Elisabeth I Heath, et al.European Urology Oncology|August 2, 2025
Outcomes for [177Lu]Lu-PSMA-617 with and Without Concurrent Use of Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration-resistant Prostate CancerMiguel Muniz, Oliver Sartor, Jacob J Orme, et al.Cancer Research|November 12, 2024
An Autophagy-Targeting Chimera Induces Degradation of Androgen Receptor Mutants and AR-v7 in Castration-Resistant Prostate CancerTae Hyun Bae, Ki Woon Sung, Tri M Pham, et al.The Oncologist|August 29, 2022
Comprehensive Genomic Profiling of Cell-Free DNA in Men With Advanced Prostate Cancer: Differences in Genomic Landscape Based on RaceRaquel Zimmerman, Mehmet A Bilen, Elisabeth I Heath, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2020
EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial CarcinomaJonathan Rosenberg, Srikala S Sridhar, Jingsong Zhang, et al.The Journal of Clinical Investigation|April 23, 2024
Renal cell carcinoma histologic subtypes exhibit distinct transcriptional profilesPedro Barata, Shuchi Gulati, Andrew Elliott, et al.Cancer Discovery|July 25, 2025
Off-pore nucleoporin sPOM121 transcriptionally propels β-Catenin driven tumor progression and immune escape in prostate cancerPerumalraja Kirthika, Vijayakumar Jawalagatti, Peiyao Li, et al.Cancer Research Communications|January 28, 2025
Expression Patterns of DLL3 across Neuroendocrine and Non-neuroendocrine Neoplasms Reveal Broad Opportunities for Therapeutic TargetingJohn R Lozada, Andrew Elliott, Mark G Evans, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2015
SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate CancerEvan Y Yu, Hongli Li, Celestia S Higano, et al.Pageof 23